Stem Cell Therapy for Liver Cirrhosis and What Current Trials Show

Liver cirrhosis represents one of the most significant unmet needs in chronic disease management. Once the liver has developed advanced scarring, conventional treatment can slow deterioration but cannot reverse the fibrosis that has already formed. This limitation is what draws researchers to stem cell therapy as a potential tool, not to replace the liver, but to reduce ongoing inflammation and fibrotic activity so that the organ's remaining functional tissue can be preserved. In Malaysia, where Hepatitis B infection remains a major driver of liver disease, this area of research carries particular relevance.

Reviewed by: Medical Team, Advance Stem Cell | Reviewed: September 2026

Understanding Liver Cirrhosis

Cirrhosis develops when chronic injury to the liver, sustained over months or years, triggers a wound-healing response that progressively replaces functional hepatocytes with scar tissue. The liver loses its capacity to produce proteins, metabolise drugs, and filter toxins. As the condition advances, complications including portal hypertension, ascites, hepatic encephalopathy, and an increased risk of hepatocellular carcinoma emerge.

The most common causes globally include chronic alcohol use, non-alcoholic fatty liver disease (NAFLD), and viral hepatitis. In Malaysia, chronic Hepatitis B infection is a leading cause of liver cirrhosis and hepatocellular carcinoma, making it a condition with significant public health implications. Hepatitis C is less prevalent in Malaysia compared to some other countries but also contributes to cirrhosis in a portion of patients.

Liver transplantation remains the only curative option for advanced cirrhosis, but donor availability, surgical eligibility criteria, cost, and the requirement for lifelong immunosuppression mean that transplantation is not an option for the majority of patients. This gap in treatment options is what motivates interest in cell-based therapies.

Why Stem Cells Are Being Studied for Cirrhosis

The liver possesses a degree of regenerative capacity that no other solid organ matches. Under normal circumstances, the liver can regenerate following partial resection or acute injury. In cirrhosis, this regenerative potential is progressively overwhelmed and suppressed by chronic inflammatory signalling and fibrotic matrix accumulation.

Researchers have been investigating mesenchymal stem cells (MSCs) as a potential therapeutic tool because of two properties that are particularly relevant to cirrhosis. First, MSCs appear to exert anti-fibrotic effects through the secretion of factors that reduce the activity of hepatic stellate cells, the cells primarily responsible for producing fibrous scar tissue in the liver. Second, MSCs have immunomodulatory properties that may dampen the chronic inflammatory processes driving ongoing liver damage.

The rationale is not that stem cells transform into new hepatocytes in meaningful numbers. That mechanism, while biologically possible in principle, appears to contribute only marginally in most clinical scenarios. The more plausible mechanism involves paracrine signalling: the cells introduced into the liver microenvironment release molecules that shift the local biological milieu toward repair rather than further injury.

What Current Clinical Evidence Shows

Several small to medium-sized clinical trials have examined whether stem cell therapy improves liver function in cirrhotic patients, with encouraging but not yet conclusive findings.

Studies using bone marrow-derived mononuclear cells and MSCs have reported improvements in selected liver function markers including MELD score (a widely used index of liver disease severity), serum albumin levels, and in some trials, reductions in serum bilirubin. A 2017 meta-analysis published in Stem Cell Research and Therapy analysed multiple trials and found that cell therapy was associated with statistically significant improvements in albumin and MELD scores compared to controls, though the authors noted that studies were small, short in duration, and heterogeneous in design.

Importantly, no large Phase 3 randomised controlled trial has yet been completed that definitively confirms the clinical efficacy of stem cell therapy for cirrhosis. The evidence base, while promising, remains at Phase 1 and 2 trial level, meaning that safety and preliminary efficacy signals have been characterised but the level of evidence required for regulatory approval as a standard treatment has not been reached.

The cells most extensively studied include autologous bone marrow-derived cells (taken from the patient's own bone marrow) and allogeneic MSCs derived from bone marrow or umbilical cord tissue. Delivery routes studied have included peripheral IV infusion, portal vein injection, and hepatic artery infusion, with different studies reporting variable results by route.

Practical Limitations and Patient Considerations

Timing and disease stage appear to be critical factors. Patients with very advanced cirrhosis, characterised by severely reduced liver volume, multi-organ involvement, or hepatic encephalopathy, may have limited capacity to respond to cell-based therapy. The more severely damaged the liver, the less remaining tissue exists to be supported or preserved.

The underlying cause of cirrhosis must also be addressed. If the driver of liver injury, whether viral, alcoholic, or metabolic, is not controlled, any potential benefit from stem cell therapy is likely to be temporary or insufficient. Patients with active Hepatitis B should be on antiviral therapy and achieve viral suppression before any experimental therapy is considered.

Patients in Malaysia who are being evaluated for any experimental liver treatment should also discuss transplant eligibility with a hepatologist. Transplant evaluation and experimental therapy are not mutually exclusive, but it is important that the possibility of transplantation is not foregone or delayed in favour of an unproven treatment. Reviewing the available treatments and conditions alongside specialist hepatology input is advisable.

Stem cell therapy Malaysia clinics offering liver cirrhosis treatment should be able to explain clearly which protocol is being applied, what the evidence base is for that specific protocol, and how outcomes will be monitored over time.

Frequently Asked Questions

Is stem cell therapy an alternative to liver transplantation for cirrhosis?

No. Stem cell therapy is not an established alternative to transplantation and cannot replace it for patients with advanced disease. It is being studied as a potential means of supporting liver function in patients who are not transplant candidates or as a way to stabilise patients while they await transplantation. Patients should discuss transplant eligibility with a hepatologist before pursuing experimental therapy.

Which type of stem cells are used in liver cirrhosis trials?

The most commonly studied cell types are mesenchymal stem cells derived from bone marrow or umbilical cord, and autologous bone marrow-derived mononuclear cells. MSCs are preferred in many current protocols because they can be produced in sufficient quantities and carry a favourable safety profile.

How is the treatment delivered for liver cirrhosis?

Routes studied include peripheral IV infusion, portal vein injection, and hepatic artery infusion. Each has a different safety and distribution profile. The choice of delivery route in any clinical protocol should be explained to the patient before treatment.

Can patients with active Hepatitis B receive stem cell therapy?

Active hepatitis with inadequately controlled viral replication would generally be considered a contraindication until viral suppression is achieved with antiviral therapy. Stable, well-controlled Hepatitis B under antiviral treatment may not necessarily exclude a patient, but specialist evaluation is required.

References

1. Shi M, et al. Autologous mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years of experience. Stem Cell Translational Medicine. 2012;1(11):821-830.
2. Peng L, et al. Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes. Hepatology. 2011;54(3):820-828.
3. Suk KT, et al. A prospective randomized controlled study investigating the efficacy and safety of granulocyte colony-stimulating factor in patients with liver cirrhosis. Journal of Hepatology. 2014;60(6):1198-1204.
4. Mohamadnejad M, et al. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World Journal of Gastroenterology. 2007;13(24):3359-3363.
5. World Health Organization. Hepatitis B. WHO Fact Sheet. Updated July 2024.

This article is for general information only. Stem cell therapies for most conditions remain experimental. Please consult a qualified doctor before pursuing any treatment.